Assessment of futility in clinical trials

被引:76
|
作者
Snapinn, Steven [1 ]
Chen, Mon-Gy [1 ]
Jiang, Qi [1 ]
Koutsoukos, Tony [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
conditional power; predictive power; predictive probability; sequential analysis; stochastic curtailment;
D O I
10.1002/pst.216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 50 条
  • [31] Early stopping in clinical trials and epidemiologic studies for "futility": Conditional power versus sequential analysis
    van der Tweel, I
    van Noord, PAH
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (07) : 610 - 617
  • [32] Improving Early Futility Determination by Learning from External Data in Pediatric Cancer Clinical Trials
    Jingjing Ye
    Gregory Reaman
    Statistics in Biosciences, 2022, 14 : 337 - 351
  • [33] Stopping clinical trials because of treatment ineffectiveness:: a comparison of a futility design with a method of stochastic curtailment
    Whitehead, J
    Matsushita, T
    STATISTICS IN MEDICINE, 2003, 22 (05) : 677 - 687
  • [34] Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction
    Asakura, Koko
    Evans, Scott R.
    Hamasaki, Toshimitsu
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (02): : 164 - 175
  • [35] The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor-Positive Breast Cancer COMMENT
    Lohmann, Ana Elisa
    Ennis, Marguerite
    Parulekar, Wendy R.
    Chen, Bingshu E.
    Tomlinson, George
    Goodwin, Pamela J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (07): : 924 - 929
  • [36] FUTILITY IN CLINICAL-PRACTICE
    SCHEETZ, A
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1995, 43 (03) : 315 - 315
  • [37] Cognition assessment in paediatric clinical trials
    Edgar, Chris J.
    Wesnes, Keith A.
    DRUG DISCOVERY TODAY, 2008, 13 (1-2) : 79 - 85
  • [38] THE ASSESSMENT OF CHANGE IN CLINICAL-TRIALS
    MAURER, W
    BIOMETRICS, 1984, 40 (01) : 268 - 268
  • [39] Relevance of cognitive assessment in clinical trials
    Benedict, R. H.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 38 - 38
  • [40] PATIENT ASSESSMENT IN CLINICAL-TRIALS
    GUY, W
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1982, 6 (4-6): : 601 - 606